affno abstract
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab2013· article· en· Clinical Gastroenterology and Hepatology· Biochemistry, Genetics and Molecular Biology
177
citations